{"id":"W4388588971","doi":"10.1093/neuonc/noad179.0259","title":"CTIM-19. ONCOLYTIC DNX-2401 VIROTHERAPY PLUS PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA: A PHASE 1/2 TRIAL","year":2023,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; Toronto Western Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Clinical endpoint; Medicine; Pembrolizumab; Oncolytic virus; Oncology; Internal medicine; Hazard ratio; Confidence interval; Phases of clinical research; Clinical trial; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000869583,0.000378965,0.0005772797,0.0004713851,0.0001381398,0.00003774311,0.000625386,0.0004925339,0.0002308259],"category_scores_gemma":[0.0004410759,0.0003521936,0.0002344453,0.0008733713,0.0002341572,0.000009266495,0.0002611425,0.0005908018,0.0003340234],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004165839,"about_ca_system_score_gemma":0.001619058,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003295881,"about_ca_topic_score_gemma":0.001228327,"domain_scores_codex":[0.9960698,0.0009432384,0.0006096131,0.000977405,0.0004118687,0.0009880497],"domain_scores_gemma":[0.9983898,0.0002481183,0.0001748744,0.0007743363,0.0000890318,0.0003238251],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.2640083,0.0008033522,0.00001775733,0.00001659716,0.00005021824,0.0003350026,0.00019148,0.0002324716,0.6658487,0.000009927905,0.01082213,0.05766408],"study_design_scores_gemma":[0.1856108,0.1197926,0.00003295146,0.00001478263,0.00002507545,0.0001215138,0.0001303903,0.001852353,0.2337582,0.0001369301,0.4579854,0.0005389327],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993633,0.0004081432,0.00004298447,0.001828019,0.001146251,0.001677908,0.000045481,0.0001084561,0.001109776],"genre_scores_gemma":[0.9927683,0.001952057,0.00004819041,0.002016053,0.001399807,0.0009208213,0.0001380599,0.0001438262,0.0006129179],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4471633,"threshold_uncertainty_score":0.999893,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03965479245783439,"score_gpt":0.3864301045020404,"score_spread":0.346775312044206,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}